Invivogen
Menu

THP1-Dual™ KO-DNase2 Cells

Product Unit size Cat. code Docs. Qty. Price

THP1-Dual™ KO-DNase2 Cells

Human THP-1 Monocytes - DNAse2 knockout NF-κB-SEAP and IRF-Lucia Reporter Cells

Show product

3-7 x 10e6 cells

thpd-kodnase2
+-
$1,752

DNase2 knockout NF-κB-SEAP and IRF-Lucia luciferase reporter monocytes

Signaling pathways in THP1-Dual™ KO-DNase2 Cells
Signaling pathways in THP1-Dual™ KO-DNase2 Cells

THP1-Dual™ KO-DNase2 cells were generated from THP1-Dual™ cells by stable biallelic knockout of the DNASE2 gene. Human THP1 monocytes or derived macrophages are a common cellular model to study DNA sensing as they naturally express all cytosolic DNA sensors identified so far (except DAI). THP1-Dual™ KO-DNase2 cells feature two inducible reporter genes allowing the concomitant study of the IRF and NF-κB pathways, by monitoring the Lucia luciferase and SEAP (secreted embryonic alkaline phosphatase) activities, respectively.

DNase2 (Deoxyribonuclease 2) is a lysosomal endonuclease present in macrophages. It exerts an important function in clearing DNA from phagocytosed apoptotic cells and from maturating erythroblast nuclei [1,2].

More details More details

 

Key features:

  • Biallelic knockout of the DNASE2 gene
  • Functionally validated with a selection of PRR ligands and cytokines
  • Readily assessable Lucia luciferase and SEAP reporter activities

Applications:

  • Study of IRF and NF-kB-dependent DNase2 signaling pathways
  • Screening of interactions between DNase2 and other signaling protein
  • Study the role of DNase2 in innate immunity

 

1. Kawane K. et al., 2014. DNA degradation and its defects. Cold Spring Harb Perspect Biol. Jun 2;6(6).
2. Crow Y.Z. & Stetson D.B., 2021. The type I interferonopathies: 10 years on. Nat Rev Immunol. Oct 20:1–13.

Figures

Validation of DNASE2 knockout
Validation of DNASE2 knockout

Figure 1: Validation of DNase2 KO. The targeted DNase2 region in THP1-Dual™ (WT; blue arrow) parental cells and THP1‑Dual™ KO-DNase2 (KO; red arrow) cells was amplified by PCR. THP1-Dual™ KO-DNase2 cells were generated by a biallelic deletion causing the inactivation of DNase2. The WT PCR product is 1133 bp, whereas the truncated KO band measures ~700 bp.

Functional validation of DNASE2 knockout (NF-κB response)
Functional validation of DNASE2 knockout (NF-κB response)

Figure 2: NF-κB responses in THP1-Dual™ -derived cells. THP1-Dual™ and THP1-Dual™ KO-DNase2 cells were incubated with 1 ng/ml human (h)TNF-α (NF-κB-SEAP positive control), 1000 U/ml hIFN-β (IRF-Lucia positive control), 10 ng/ml LPS-EK Ultrapure (UP; TLR4 agonist), 10 µg/ml CL075 (TLR7/8 agonist), 1 µg/ml VacV70 complexed with LyoVec™ (CDS agonist), 1 µg/ml 3p-hpRNA complexed with LyoVec™ (RIG-I agonist) and 30 µg/ml 2’3’-cGAMP (STING agonist). After overnight incubation, the activation of NF-κB was assessed by measuring the activity of SEAP in the supernatant using QUANTI‑Blue™ Solution. Data are shown as optical density (OD) at 630 nm (mean ± SEM).

 


Figure 3: IRF responses in THP1-Dual™ -derived cells. THP1-Dual™ and THP1-Dual™ KO-DNase2 cells were incubated with 1 ng/ml human (h)TNF-α (NF-κB-SEAP positive control), 100 ng/ml LPS-EK Ultrapure (TLR4 agonist), 10 µg/ml CL075, 10 µg/ml R848 (both TLR7/8 agonists), 1 µg/ml VacV70 complexed with LyoVec™ (CDS agonist), 1 µg/ml 3p-hpRNA complexed with LyoVec™ (RIG-I agonist) and 30 µg/ml 2’3’-cGAMP (STING agonist). After overnight incubation, the IRF response was assessed by measuring the activity of Lucia luciferase in the supernatant using QUANTI‑Luc™. The IRF induction of each ligand is expressed relative to that of hIFN-β at 1x10³ U/ml (mean ± SEM).

Back to the top

Specifications

Growth medium: RPMI 1640, 2 mM L-glutamine, 25 mM HEPES, 10% heat-inactivated fetal bovine serum, 100 U/ml Penicillin, 100 μg/ml Streptomycin, 100 μg/ml Normocin™

Antibiotic resistance: Zeocin®Blasticidin

Quality control: 

  • Biallelic DNASE2 gene knockout has been verified by PCR, DNA sequencing, and functional assays.
  • The stability of this cell line for 20 passages following thawing has been verified.
  • THP1-Dual™ KO-DNase2 cells are guaranteed mycoplasma-free.

This product is covered by a Limited Use License (See Terms and Conditions).

Back to the top

Contents

  • 1 vial of THP1-Dual™ KO-DNase2 cells (3-7 x 106 cells)  in a cryovial or shipping flask
  • 1 ml of Normocin™ (50 mg/ml). Normocin™ is a formulation of three antibiotics active against mycoplasmas, bacteria, and fungi.
  • 1 ml of Zeocin® (100 mg/ml)
  • 1 ml of Blasticidin (10 mg/ml)
  • 1 tube of QUANTI-Luc™ 4 Reagent, a Lucia luciferase detection reagent (sufficient to prepare 25 ml)
  • 1 ml of QB reagent and 1 ml of QB buffer (sufficient to prepare 100 ml of QUANTI-Blue™ Solution, a SEAP detection reagent)

Dry Ice Shipped on dry ice (Europe, USA, Canada and some areas in Asia)

Back to the top

Details

DNase2 (alternatively known as DNase II, DNase2a, or Acid DNase) is an endonuclease critical in cellular health and development.

It is localized in the lysosome of macrophages and shows peak activity at an acidic pH [2]. This enzyme is involved in DNA metabolism: it digests exogenous DNA of apoptotic cells and DNA of nuclei expelled from erythroid precursors [1].  Like TREX1, another critical nuclease also known as DNase III, DNase2 helps to rapidly remove nucleic acid fragments to prevent cells from accumulating self-DNA in the cytosol and triggering autoimmunity [3].

Defects in DNase2 functions allow undigested DNA fragments to leak into the cytosol and trigger the STING-TBK1-IRF3 signaling pathway [1]. As a consequence, pro-inflammatory cytokines (e.g., IFN-β) are constitutively expressed, causing interferonopathies and other autoimmune disease phenotypes (e.g. severe anemia, arthritis) [2,4].

 

1. Rodero et al., 2017. Type I interferon-mediated autoinflammation due to DNase II deficiency. Nat Commun 8, 2176.
2. Keyel, 2017. Dnases in health and disease. Developmental Biology 429(1).
3. Lan, Y.Y. et al., 2014. “Dnase2a deficiency uncovers lysosomal clearance of damaged nuclear DNA via autophagy.” Cell reports vol. 9,1: 180-192.
4. Crow, Y.J. &Stetson, D.B. 2021. The type I interferonopathies: 10 years on. Nat Rev Immunol.

Back to the top

FAQ Cell Lines

Visit our FAQ Any questions about our cell lines ? Visit our frequently asked questions page

Back to the top

Notification:  This product is for internal research use only. Additional rights may be available. Please visit InvivoGen’s Terms and Conditions.

Customer Service
& Technical Support
Shopping cart is empty